Sanofi beats Q3 on Dupixent, raises guidance, adds $8B Regeneron pact
Alpha Vantage · TradingView · · AI-summarised by FinFlash
Sanofi SA (SAN) reported beating Q3 expectations primarily due to Dupixent sales, leading to raised full-year guidance despite lagging vaccines and Beyfortus. The company also reshuffled its management, extended an $8 billion pact with Regeneron for drug development and dispute resolution, and generally maintains a "buy" rating from analysts despite some recent estimate reductions.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.